Colistimethate sodium dry powder inhalation - Allergan

Drug Profile

Colistimethate sodium dry powder inhalation - Allergan

Alternative Names: Colistimethate sodium inhalation powder - Forest; Colobreathe

Latest Information Update: 28 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Forest Laboratories
  • Developer Allergan
  • Class Antibacterials; Polymixins
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections

Most Recent Events

  • 28 Apr 2017 No recent reports on development identified - Preregistration for Cystic fibrosis-associated respiratory tract infections in Brazil (Inhalation)
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 06 Jan 2014 Preregistration for Cystic fibrosis-associated respiratory tract infections in Brazil (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top